<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978481</url>
  </required_header>
  <id_info>
    <org_study_id>B-1902-523-107</org_study_id>
    <nct_id>NCT03978481</nct_id>
  </id_info>
  <brief_title>Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study</brief_title>
  <official_title>Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will observe the long-term survival rate, overall mortality rate, gastric
      cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who
      received subtotal gastrectomy, with or without Helicobacter pylori eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will observe the long-term survival rate, overall mortality rate, gastric
      cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who
      received subtotal gastrectomy, with or without Helicobacter pylori eradication. In addition,
      we will analyze the correlation between the incidence and survival rate of this type of
      stomach cancer by comparing smoking, gastric cancer direct family history, disease stage (TNM
      staging), the histologic type of stomach cancer (intestinal, diffuse, mixed), and the
      surgical method (Billoth I, Billoth II) as well as the infection and eradication status of H.
      pylori.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of initial curative surgery for gastric cancer, until the date of death from any cause, up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer-specific (disease-free) survival</measure>
    <time_frame>From date of initial curative surgery for gastric cancer, until the date of diagnosis of gastric cancer recurrence or the date of death, whichever comes first, up to 60 months</time_frame>
    <description>Survival period without cancer recurrence or newly developed stomach cancer diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metachronous cancer (remnant stomach cancer)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>The number of patients who were diagnosed with new carcinoma on the remnant stomach, over follow-up period of up to 60 months, in eradication group and non-eradication group</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3800</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Eradicated group</arm_group_label>
    <description>Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative group</arm_group_label>
    <description>Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Helicobacter pylori eradication (combination therapy)</intervention_name>
    <description>Antibiotic eradication therapy (triple or quadriple regimen)</description>
    <arm_group_label>Eradicated group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with gastric cancer and received surgery (partial, distal, subtotal
        gastrectomy), and tested Helicobacter pylori status in Seoul National University Bundang
        Hospital, from 2003 to 2018
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with gastric cancer and received surgery (partial, distal, subtotal
             gastrectomy), and tested Helicobacter pylori status

        Exclusion Criteria:

          -  Patients with other severe diseases (other primary cancer, severe cardiovascular,
             cerebral, renal, hepatic diseases)

          -  Patients received palliative treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nayoung Kim, M.D., Ph. D.</last_name>
    <phone>82-31-787-7008</phone>
    <email>nayoung49@empas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayoung Kim</last_name>
      <phone>82317877009</phone>
      <email>nayoungkim49@empas.com</email>
    </contact>
    <contact_backup>
      <last_name>Sohn</last_name>
      <phone>821052164932</phone>
    </contact_backup>
    <investigator>
      <last_name>Nayoung Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Nayoung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Subtotal gastrectomy</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Metachronous cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

